Paper Details

  1. Home
  2. Paper Details

Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents.

Author: FonsecaVivian A, GranberryMark C

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This article reviewed the effects of various oral antidiabetic drugs on cardiovascular risk factors in patients with type 2 diabetes mellitus. The study found that thiazolidinediones improve hemostasis and endothelial function, reduce blood pressure, and have variable effects on dyslipidemia. Metformin improves dyslipidemia and altered hemostasis, decreases plasma C-reactive protein levels, and has little or no effect on blood pressure. Data on the effects of alpha-glucosidase inhibitors and insulin secretagogs are sparse but suggest that these drugs have little or no effect on cardiovascular risk factors.
Paper Details　
Original Abstract of the Article :
Patients with type 2 diabetes mellitus have a greater risk of cardiovascular disease than nondiabetic individuals. These patients are often insulin resistant and have an associated clustering of risk factors that contribute to cardiovascular disease. The risk factors include dyslipidemia, hypertensi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/00129784-200505030-00006

データ提供：米国国立医学図書館（NLM）

Managing Diabetes and Cardiovascular Risk: The Role of Oral Antidiabetic Agents

Type 2 diabetes mellitus, a chronic condition affecting millions of people worldwide, is often accompanied by a cluster of cardiovascular risk factors, increasing the likelihood of heart disease. This study explores the impact of oral antidiabetic agents on these risk factors, examining their potential to improve cardiovascular health in individuals with type 2 diabetes.

Taming the Metabolic Desert: Oral Antidiabetic Agents and Cardiovascular Risk

The study reveals that different classes of oral antidiabetic agents have varying effects on cardiovascular risk factors. For example, thiazolidinediones can improve hemostasis, endothelial function, and blood pressure, while metformin can improve dyslipidemia and reduce inflammation. This research provides valuable insights into the complex interplay between diabetes management and cardiovascular health, highlighting the need for individualized treatment approaches.

Finding a Balanced Path: Managing Diabetes and Cardiovascular Risk

This study underscores the importance of considering the cardiovascular impact of antidiabetic medications. It's like navigating a desert landscape, where different paths lead to different destinations. Choosing the right medication can help individuals manage their diabetes effectively while minimizing the risk of cardiovascular complications. This research empowers patients and physicians to make informed decisions that promote both blood sugar control and heart health.

Dr.Camel's Conclusion

This study explores the impact of oral antidiabetic agents on cardiovascular risk factors in individuals with type 2 diabetes. It's like finding a hidden oasis in the vast desert of metabolic disease – a place where we can manage both blood sugar and heart health. This research highlights the importance of individualized treatment approaches to optimize both diabetes management and cardiovascular well-being.

Date :
  1. Date Completed 2006-08-08
  2. Date Revised 2018-10-25
Further Info :

Pubmed ID

15901207

DOI: Digital Object Identifier

10.2165/00129784-200505030-00006

Related Literature

Article Analysis
・Effects of tolazamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.